Table 1 Clinicopathological characteristics of the patients
From: Impact of DAXX and ATRX expression on telomere length and prognosis of breast cancer patients
Variable | Number of cases (%) |
|---|---|
Age | |
< 40 years | 86 (39%) |
≥ 40 years | 134 (61%) |
Tumor size | |
Mean ± SD | 4.68 ± 2.15 |
Tumor grade | |
GI | 30 (13.6) |
GII | 130 (59.1) |
GII | 60 (27.3) |
Necrosis | |
Absent | 114 (51.8%) |
Present | 106 (48.2%) |
Vascular invasion | |
Absent | 82 (37.3%) |
Present | 138 (62.7%) |
TILs | |
Focal | 64 (29.1%) |
LPBC | 156 (70.9%) |
Lymph node metastasis | |
N0 | 90 (40.9%) |
N1 | 40 (18.2%) |
N2 | 36 (16.4%) |
N3 | 54 (24.5%) |
Stages | |
Stage IB | 8 (3.6%) |
Stage IIA | 84 (38%) |
Stage IIB | 34 (15%) |
Stage IIIA | 22 (10.2%) |
Stage IIIB | 18 (8.3%) |
Stage IIIC | 54 (24.9%) |
Hormonal status | |
ER and PR negative | 82 (37.3%) |
ER and/or PR positive | 138 (62.7%) |
HER2/neu | |
Negative | 138 (62.7%) |
Positive | 82 (37.3%) |
Mol. classification of BC | |
Luminal A | 103 (47%) |
Luminal B | 39 (18%) |
HER2/neu +ve | 43 (19%) |
Triple negative | 35 (16%) |
Status | |
Living | 170 (77.2%) |
Dead | 50 (22.8%) |
Recurrence | |
Absent | 130 (59.8%) |
Present | 90 (39.2%) |